PKP: MEDEX – The effects of royal jelly on systemic inflammation


Duration of the project:

1. 3. 2018 – 30. 6. 2018

Project leader:

Assist. Prof. Zala Jenko Pražnikar (SICRIS, ResearchGate)

Other participants:

Assist. Prof. Ana Petelin (SICRIS, ResearchGate)
Assist. Prof. Mojca Stubelj (SICRIS, ResearchGate)
Helena Skočir (SICRIS)

Project partners:

Medex, d.o.o. 


Obesity and overweight are chronic disorders of multifactorial origin, characterized by a high oxidative status and chronic activation of macrophages in peripheral tissues. Effective therapeutic approaches to reduce inflammation and oxidative stress are currently of general interest. Royal jelly (RJ) is a functional food with a wide range of pharmacological activities used by healthy individuals or borderline patients to protect them against the onset of disease. The aim of this randomized, double-blind, placebo-controlled study was to investigate the effects of royal jelly supplementation (from the company MEDEX) on oxidative and inflammatory parameters in asymptomatic overweight adults considered to be at an early stage of the development of the metabolic syndrome. The present study showed positive effects of RJ administration on lipid profile, satiety, inflammation and antioxidant capacity in overweight adults. Therefore, our study supports the benefits of RJ supplementation for the improvement of human health.

»The authors acknowledge the project MEDEX is finacially supported by the European Social Fund (80%) and Ministry of Education, Science and Sport (20%).«